Impact Biomedical (IBO) Gross Margin (2025 - 2026)

Impact Biomedical's (IBO) quarterly Gross Margin came in at 94.44% in Q3 2025, up 265.28% on a QoQ basis from 57.14% in Q2 2025.

Impact Biomedical (IBO) Gross Margin (2025 - 2026) Analysis & Trends

Impact Biomedical (IBO) has 1 years of Gross Margin data on file, last reported at 94.44% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	91.59%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	90.43%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	35.86%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	89.76%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	76.90%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	84.20%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	63.27%
10	Impact Biomedical	49.45 Mn	49.44 Mn	2,000.00	66.67%

Download Data